{"Clinical Trial ID": "NCT00107276", "Intervention": ["INTERVENTION 1:", "- Cyclophosphamide and capecitabine", "1-14 days oral and capecitabine 15-21 days oral for 8 cycles of 21 days each"], "Eligibility": ["CHARACTERISTICS OF DISEASE:", "Stage IV breast cancer confirmed histologically or cytologically", "A metastatic disease (M1) OR multiple sites of new disease that is clinically obvious metastatic disease (i.e. several sites of new bone disease)", "Meets 1 of the following criteria:", "A Measurable Disease", "A non-measurable disease", "The level of MUC-1 antigen > 2 times the upper limit of normal AND the level increased 1.5 times", "\u2022 Must have documented the level of MUC-1 antigen", "Either cancer antigen (CA) 15-3 or CA 27-29 is allowed", "Must have received at least 1 prior hormonal treatment for metastatic disease (positive-receptor patients only)", "No symptomatic CNS or brain metastases", "A previously treated CNS or brain metastasis is allowed provided radiotherapy is completed 8 weeks prior to entry into the study.", "- Hormonal receptor status:", "Unspecified", "CHARACTERISTICS OF PATIENTS:", "Age", "- 18 years and over", "Gender", "Women", "Status of menopause", "Unspecified", "State of play", "- Zubrod 0-2", "Life expectancy", "Unspecified", "Haematopoietic", "No known uncontrolled coagulopathy", "Hepatic", "Unspecified", "Renal", "creatinine clearance > 40 mL/min", "Cardiovascular disorders", "No congestive heart failure", "No symptomatic coronary artery disease", "No cardiac arrhythmia is well controlled by medicines", "No myocardial infarction in the last 12 months", "No other clinically significant heart disease", "Gastrointestinal toxicity", "\u2022 Capable of taking oral medicines", "No uncontrolled nausea, vomiting or diarrhoea", "No lack of physical integrity of the upper gastrointestinal tract", "No malabsorption syndrome", "Other", "No pregnancy or breast-feeding", "Fertile patients should use effective contraception", "No active infection requiring systemic treatment", "No previous severe reactions to fluoropyrimidines", "No known fluoruracil sensitivity", "No known dihydropyrimidine dehydrogenase deficiency", "No other malignancy in the last 5 years, except skin cancer or in situ carcinoma of the treated basal cell or squamous cell", "THERAPE PRIOR CONCURENT:", "Biological therapy", "No simultaneous immunotherapy or biological therapy for breast cancer", "No concurrent gene therapy for breast cancer", "No competing filgrastim (G-CSF)", "- Chemotherapy", "At least 14 days from previous chemotherapy and recovered", "No more than 2 chemotherapys for metastatic diseases", "No anterior capecitabine for metastatic disease", "No previous oral cyclophosphamide for metastatic disease", "Previous IV cyclophosphamide permitted", "No other concomitant chemotherapy for breast cancer", "Endocrinotherapy", "See Disease Characteristics", "No concomitant hormonal treatment for breast cancer", "Radiotherapy", "See Disease Characteristics", "At least 14 days from prior radiotherapy at non-NCS sites and recovered", "No simultaneous radiotherapy for breast cancer", "Surgery", "Unspecified", "Other", "Allowed concurrent biphosphonates", "No concomitant complete dose of warfarin", "\u2022 Concomitant prophylactic warfarin ( 1 mg/day) to maintain the authorized port licence", "No other concomitant antineoplastic therapy for breast cancer"], "Results": ["Performance measures:", "Response rate (complete and partial, confirmed and unconfirmed)", "The partial response (PR) is greater than or equal to 30% of the sum of the longest diameters of all target measurable lesions. No unequivocal progression of the non-measurable disease. No new injury. Confirmation of the CR or RA means a repeated scan of at least 4 weeks before the symptomatic progression or deterioration. Progression is 20% increase in the sum of the longest diameters of target measurable lesions on the smallest amount observed and/or unequivocal progression of the non-measurable disease and/or the appearance of new lesions/site or deaths due to a disease without advance documentation and without symptomatic deterioration. Symptomatic deterioration is an overall deterioration of the health condition requiring discontinuation of treatment without objective evidence of progression.", "Delay: Patients were evaluated at least every six weeks during protocol therapy.", "Results 1:", "Title of the arm/group: Cyclophosphamide and Capecitabine", "Description of the arm/group: oral cyclophosphamide days 1-14 and oral capecitabine days 15-21 for 8 cycles of 21 days each", "Total number of participants analysed: 80", "Type of measurement: Number", "Unit of measurement: participants 29"], "Adverse Events": ["Undesirable Events 1:", "Total: 4/95 (4.21%)", "Deaths not associated with the term CTCAE - Deaths NOS 1/95 (1.05 %)", "Death - progression of disease NOS 2/95 (2.11 %)", "CNS cerebrovascular ischemia 1/95 (1.05%)"]}